Frank Lammert, David Q.-H. Wang  Gastroenterology 

Slides:



Advertisements
Similar presentations
Cholesterol Metabolism
Advertisements

Cholesterol synthesis and breakdown Dr. Carolyn K. Suzuki 1.
Lipid Homeostasis and Transport CH353 February 12, 2008.
Cholesterol Metabolism and the Concept of Dual Inhibition David E. Cohen, MD, PhD.
Overview Lipoprotein metabolism Digestive lipid metabolism
Cholesterol metabolism
Lymphatics as a New Active Player in Reverse Cholesterol Transport
Volume 154, Issue 3, Pages (February 2018)
Lipids in Liver Disease: Looking Beyond Steatosis
Elizabeth P. Newberry, Nicholas O. Davidson  Gastroenterology 
Vitamin D and the Parenteral Nutrition Patient
The FXR-FGF19 Gut–Liver Axis as a Novel “Hepatostat”
Volume 146, Issue 4, Pages (April 2014)
Volume 148, Issue 1, Pages (January 2015)
Volume 134, Issue 7, Pages (June 2008)
Byeong–Moo Kim, Michael Y. Choi  Gastroenterology 
SMAD About Hepatitis C Virus Cell Entry and Liver Disease
Volume 146, Issue 4, Pages (April 2014)
HCV NS5A Inhibitors: The Devil Is in the Details
IPA1: A New “Green Revolution” Gene?
Gallstone Disease and Cancer Risk: Finding the Bug in the System
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,
My Approach to the Patient With Familial Hypercholesterolemia
SUMOylation Places LRH-1 in PROXimity to Lipid Metabolism
Volume 149, Issue 7, Pages (December 2015)
Ezetimibe Blocks Internalization of the NPC1L1/Cholesterol Complex
Advanced Nutrition Lipids 5 MargiAnne Isaia, MD MPH.
Pascal Ferré, Fabienne Foufelle  Cell Metabolism 
Volume 149, Issue 6, Pages (November 2015)
Volume 7, Issue 5, Pages (May 2008)
Ronald P.J. Oude Elferink, Coen C. Paulusma, Albert K. Groen 
Molecular aspects of iron absorption and HFE expression
Short-Bowel Syndrome Clinical Gastroenterology and Hepatology
SUMOylation Places LRH-1 in PROXimity to Lipid Metabolism
New Therapeutic Approaches to the Treatment of Dyslipidemia
Volume 130, Issue 6, Pages (May 2006)
Guido T. Bommer, Ormond A. MacDougald  Cell Metabolism 
Hyperbilirubinemia in the setting of antiviral therapy
Figure 1 Intestinal action of functional foods and supplements
Copyright © 2016 Elsevier Inc. All rights reserved.
Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate
Volume 134, Issue 4, Pages (April 2008)
Singling Out Intestinal Epithelial Stem Cells
Host-targeting agents for prevention and treatment of chronic hepatitis C – Perspectives and challenges  Mirjam B. Zeisel, Joachim Lupberger, Isabel Fofana,
Emina Halilbasic, Thierry Claudel, Michael Trauner 
Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease  Guenther Silbernagel, MD, Iris Baumgartner, MD, Christoph Wanner, MD,
Daniel J. Rader, Ellen Puré  Cell Metabolism 
Volume 7, Issue 5, Pages (May 2008)
Biff F. Palmer, MD  American Journal of Kidney Diseases 
The genetics of alcohol dependence and alcohol-related liver disease
HCV, Iron, and Oxidative Stress: The New Choreography of Hepcidin
Chronic Diarrhea Due to Excessive Bile Acid Synthesis and Not Defective Ileal Transport: A New Syndrome of Defective Fibroblast Growth Factor 19 Release 
In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstruction  François Moreau, PhD, Claire Blanchard,
Volume 150, Issue 5, Pages (May 2016)
A View to Natural Killer Cells in Hepatitis C
Covering the Cover Gastroenterology
Diarmaid Dominic Houlihan, Philip Noel Newsome  Gastroenterology 
When Bile Acids Don't Get Amidated
Daniel J. Rader, Ellen Puré  Cell Metabolism 
Lipids in Liver Disease: Looking Beyond Steatosis
Foxf2: A Mesenchymal Regulator of Intestinal Adenoma Development
Gerd A. Kullak-ublick, Bruno Stieger, Peter J. Meier  Gastroenterology 
Ikuo Nakamura, Lewis R. Roberts  Gastroenterology 
Genetics of Hepatobiliary Diseases
Would Free Fatty Acids Enhance Treatment of Obesity?
Advances in the pathogenesis of HIV-associated kidney diseases
Nosratola D. Vaziri, M.D., Kaihui Liang  Kidney International 
Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis  Nosratola D. Vaziri, Tadashi Sato, Kaihui Liang 
An Orphan Meets Family Members in Skin
Stephen A. Harrison  Clinical Gastroenterology and Hepatology 
Presentation transcript:

New Insights Into the Genetic Regulation of Intestinal Cholesterol Absorption  Frank Lammert, David Q.-H. Wang  Gastroenterology  Volume 129, Issue 2, Pages 718-734 (August 2005) DOI: 10.1053/j.gastro.2004.11.017 Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Intestinal cholesterol absorption is a multistep process that is regulated by multiple genes. The Niemann-Pick C1-like 1 protein (NPC1L1), a newly identified sterol influx transporter, is located at the apical membrane of the enterocyte, which may actively facilitate the uptake of cholesterol. ABCG5 and ABCG8 promote active efflux of cholesterol and plant sterols from the enterocyte into the intestinal lumen for excretion. The combined regulatory effects of NPC1L1, ABCG5, and ABCG8 may play a critical role in modulating the amount of cholesterol that reaches the lymph from the intestinal lumen. In addition, several proteins involved in other steps in the absorption process, eg, liver X receptor α (LXRα), acyl-CoA:cholesterol acyltransferase isoform 2 (ACAT2), apolipoprotein B48 (APO-B48), and microsomal triglyceride transfer protein (MTP) in the enterocyte, may exert major influences on cholesterol absorption. Furthermore, the efficiency of intestinal cholesterol absorption may be determined by a balance between influx and efflux of intraluminal cholesterol molecules across the apical brush board membrane of the enterocyte. The principal mechanism whereby hydrophilic bile acids inhibit cholesterol absorption appears to be via diminution of intraluminal micellar cholesterol solubilization. Plant sterols and plant stanols have a higher affinity to mixed micelles than does cholesterol, and they thereby displace cholesterol from these micelles and reduce cholesterol absorption. It is most likely that ezetimibe could reduce cholesterol absorption by inhibiting the activity of intestinal NPC1L1. Modified from Duan et al124 with permission. Gastroenterology 2005 129, 718-734DOI: (10.1053/j.gastro.2004.11.017) Copyright © 2005 American Gastroenterological Association Terms and Conditions